Aarti Pharmalabs Approves Q1 FY27 Results, Capex of ₹149 Crore, and Key Management Changes
Aarti Pharmalabs reported Q1 FY27 results with standalone revenue of ₹534.59 crore and net profit of ₹71.31 crore. Consolidated revenue was ₹535.80 crore with net profit of ₹76.14 crore. The company approved a ₹149 crore capex for capacity expansion and key management changes, appointing Rashesh C. Gogri as Managing Director and Hetal Gogri Gala as Executive Director, effective October 1, 2026.
The substantial capital expenditure for capacity addition and significant management role changes are material events that will likely have a considerable impact on the company's future operations and strategic direction.
The approval of financial results, significant capex for expansion, and key management changes indicate positive operational and strategic developments for the company.
Aarti Pharmalabs Limited announced the outcome of its Board Meeting held on August 7, 2026. The Board approved the unaudited financial results for the quarter ended June 30, 2026, both standalone and consolidated.
Key management changes were also approved, with Shri Rashesh C. Gogri transitioning from Non-Executive Director to Managing Director, and Smt. Hetal Gogri Gala moving from Managing Director to Executive Director. These changes are effective October 1, 2026, and are subject to shareholder approval at the upcoming Annual General Meeting.
The company also approved a significant capacity addition for an Intermediate Block with an estimated capital expenditure of ₹149 Crores. This expansion is intended to serve intermediate and CDMO customers and will be financed through internal accruals and borrowings, with completion expected within one year.
Furthermore, the Board approved the reconstitution of the Audit Committee, Corporate Social Responsibility (CSR) Committee, and Stakeholders Relationship Committee, effective October 1, 2026, for the Audit and CSR committees, and with immediate effect for the Stakeholders Relationship Committee.
The Board Meeting commenced at 2:00 p.m. and concluded at 6:00 p.m. The financial results indicate standalone revenue from operations of ₹53,458.78 lakhs and a net profit of ₹7,130.66 lakhs for the quarter ended June 30, 2026. Consolidated revenue from operations stood at ₹53,579.69 lakhs with a net profit of ₹7,614.27 lakhs for the same period.
What to do with a filing like this
Aarti Pharmalabs Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarti Pharmalabs Limited. Read the original for the full detail.